The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serum Bio-markers in Pulmonary Hypertension

NCT04472533

Pulmonary Hypertension, Primary, 4

COMPLETED

Surfactant Associated Protein - A Novel Marker for the Diagnosis of Pulmonary Embolism

NCT01353365

Pulmonary Embolism

UNKNOWN

The Coagulation Cascade in Idiopathic Pulmonary Fibrosis

NCT02885961

Idiopathic Pulmonary Fibrosis IPF Interstitial Lung Disease

UNKNOWN NA

The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

NCT06192199

Acute Pulmonary Embolism

RECRUITING

MLPR As A Diagnostic Marker For Acute Pulmonary Embolism

NCT07023705

Pulmonary Embolism (Diagnosis) Diagnosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Lung Diseases Hemoptysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with hemoptysis within 2 weeks

No interventions assigned to this group

patients without hemoptysis within 2 years

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung

Exclusion Criteria

* patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No